Analysts Set CVRx, Inc. (NASDAQ:CVRX) Target Price at $14.00

Key Points

• CVRx, Inc. has received a consensus rating of "Moderate Buy" from seven brokerages, with one sell rating, five buy ratings, and one strong buy rating.
• The average 12-month target price for CVRx shares is $14.00, while current trading is around $7.87.
• The company's quarterly earnings report revealed a loss of ($0.57) EPS, slightly worse than analyst estimates, with revenues beating expectations at $13.59 million.

CVRx, Inc. (NASDAQ:CVRX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $14.00.

A number of equities analysts have issued reports on the company. William Blair raised CVRx to a "strong-buy" rating in a research report on Monday, July 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $11.00 target price on shares of CVRx in a research report on Tuesday, August 5th.

CVRx Stock Up 5.8%

Shares of CVRX traded up $0.39 during trading on Friday, reaching $7.17. The company's stock had a trading volume of 199,534 shares, compared to its average volume of 158,196. The company has a fifty day moving average of $7.65 and a two-hundred day moving average of $7.83. CVRx has a twelve month low of $4.30 and a twelve month high of $18.55. The company has a market cap of $187.50 million, a price-to-earnings ratio of -3.41 and a beta of 1.26. The company has a quick ratio of 10.78, a current ratio of 11.99 and a debt-to-equity ratio of 0.85.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05). CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. The business had revenue of $13.59 million during the quarter, compared to analyst estimates of $13.22 million. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts predict that CVRx will post -1.91 EPS for the current fiscal year.

Institutional Investors Weigh In On CVRx

Institutional investors and hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC acquired a new stake in shares of CVRx during the 1st quarter valued at approximately $28,000. Mount Lucas Management LP acquired a new stake in shares of CVRx during the 2nd quarter valued at approximately $30,000. GAMMA Investing LLC raised its position in shares of CVRx by 1,469.3% during the 1st quarter. GAMMA Investing LLC now owns 4,598 shares of the company's stock valued at $56,000 after acquiring an additional 4,305 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of CVRx during the 2nd quarter valued at approximately $59,000. Finally, Whittier Trust Co. acquired a new stake in shares of CVRx during the 1st quarter valued at approximately $73,000. 75.27% of the stock is owned by institutional investors and hedge funds.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.